Special Issue "Applications of Nano-Designed Systems in Biomedical Research"

A special issue of Nanomaterials (ISSN 2079-4991).

Deadline for manuscript submissions: closed (30 June 2019).

Special Issue Editor

Prof. Dr. Amnon Sintov
Website
Guest Editor
Ben-Gurion University of the Negev, Department of Biomedical Engineering, Be’er Sheva 84105, Israel
Interests: transdermal and topical drug delivery; intranasal administration of nano-metric systems; microemulsions; nanoparticles; biopharmaceutics
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

Nano-designed technologies have gained a great deal of interest, which is expressed by an extensive worldwide use; in diverse research areas, in many products, and in various industrial processes. Due to the unique properties of nano-designed systems as potential nanocarriers through biological barriers, their application in drug therapeutics is an important issue that should be specifically addressed. Thus, in an attempt to highlight the medical uses and applications related to nano-designed compositions, Nanomaterials has decided to publish a Special Issue “Applications of Nano-Designed Systems in Biomedical Research”, which will focus on recent studies and developments of nanosystems for the delivery for drugs and therapeutic agents. The Special Issue of Nanomaterials will include:

  • Recent advances in theoretical modeling of drug solubilization and release from nanotechnology-based systems.
  • Oral delivery and intestinal absorption of drug-loaded nanoparticles.
  • Delivery of protein and peptide drugs via nano-systems
  • Parenteral delivery and tumor targeting.
  • Topical and dermatological use.
  • Intranasal and brain targeting.
  • Other applications (e.g., ophthalmic, periodontal, etc.).
  • Methods and procedures for the manufacture of drug nanocarriers.

Prof. Amnon Sintov
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Nanoparticles, nanospheres, nanocapsules, nanoprisms
  • Microemulsion, nanoemulsion
  • Self-assembling nanostructures
  • Enhanced drug delivery
  • Increased drug bioavailability
  • Protein and peptide drug delivery
  • Sustained and targeted drug delivery

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
Spray-Dried, Nanoencapsulated, Multi-Drug Anti-Tuberculosis Therapy Aimed at Once Weekly Administration for the Duration of Treatment
Nanomaterials 2019, 9(8), 1167; https://doi.org/10.3390/nano9081167 - 15 Aug 2019
Cited by 1
Abstract
Aiming to improve the treatment outcomes of current daily tuberculosis (TB) chemotherapy over several months, we investigated whether nanoencapsulation of existing drugs would allow decreasing the treatment frequency to weekly, thereby ultimately improving patient compliance. Nanoencapsulation of three first-line anti-TB drugs was achieved [...] Read more.
Aiming to improve the treatment outcomes of current daily tuberculosis (TB) chemotherapy over several months, we investigated whether nanoencapsulation of existing drugs would allow decreasing the treatment frequency to weekly, thereby ultimately improving patient compliance. Nanoencapsulation of three first-line anti-TB drugs was achieved by a unique, scalable spray-drying technology forming free-flowing powders in the nanometer range with encapsulation efficiencies of 82, 75, and 62% respectively for rifampicin, pyrazinamide, and isoniazid. In a pre-clinical study on TB infected mice, we demonstrate that the encapsulated drugs, administered once weekly for nine weeks, showed comparable efficacy to daily treatment with free drugs over the same experimental period. Both treatment approaches had equivalent outcomes for resolution of inflammation associated with the infection of lungs and spleens. These results demonstrate how scalable technology could be used to manufacture nanoencapsulated drugs. The formulations may be used to reduce the oral dose frequency from daily to once weekly in order to treat uncomplicated TB. Full article
(This article belongs to the Special Issue Applications of Nano-Designed Systems in Biomedical Research)
Show Figures

Figure 1

Back to TopTop